Refractory Hodgkin’s disease represents one of the most challenging scenarios in lymphoma care. When this cancer stops responding to standard treatments or returns after therapy, patients and their families face difficult decisions about next steps. However, ongoing advances in medical research are bringing new possibilities to those who need them most.

Navigating Treatment When Cancer Doesn’t Respond as Expected

When someone hears that their Hodgkin lymphoma is refractory, it means the disease is not behaving as doctors hoped. The term refractory describes cancer that does not respond to treatment, meaning that cancer cells continue to grow even while therapy is being administered, or the response to treatment does not last very long. This is different from relapsed disease, which refers to cancer that reappears or grows again after a period of remission, when the disease was not detectable in the body.^[1]

For classical Hodgkin lymphoma, most relapses typically happen within the first three years following the initial diagnosis, although some patients experience disease return much later. The reality is that approximately one-third of all Hodgkin lymphoma patients will not have a complete response to their first-line treatment or will experience a relapse later on. Among these patients, conventional therapies successfully treat only about half, leaving a significant number who need additional or different approaches.^[3]

The primary goals of treating refractory Hodgkin’s disease focus on controlling symptoms, achieving remission whenever possible, and improving quality of life. The choice of treatment depends heavily on several personal factors. Doctors consider the timing of the disease’s reappearance, the patient’s age and overall health, how widespread the lymphoma is throughout the body, and what therapies the person has already received. These factors help guide healthcare teams toward the most appropriate next steps for each individual situation.^[1]

It’s important to understand that while refractory disease presents serious challenges, secondary therapies can often still provide another remission and may even result in long-term disease control or cure for some patients. Modern medicine has made significant strides in understanding how Hodgkin lymphoma behaves and how to combat it when it proves resistant to initial treatment approaches.^[1]

Standard Treatment Approaches for Refractory Disease

When Hodgkin lymphoma proves refractory to initial therapy, the standard approach for most patients involves combination chemotherapy, typically followed by a stem cell transplant. This represents the backbone of treatment that medical guidelines recommend for patients whose disease has not responded adequately or has returned after initial treatment.^[1]

Chemotherapy Regimens

Doctors have several chemotherapy combinations at their disposal for treating refractory Hodgkin lymphoma. Sometimes, if the disease responded well to the original chemotherapy drugs the first time they were given, doctors may choose to use that same combination again. More often, however, they will select a different combination of drugs to overcome the resistance the cancer cells have developed.^[2]

Common chemotherapy combinations used for refractory Hodgkin lymphoma include several well-established regimens. The DHAP regimen combines dexamethasone, cisplatin, and cytarabine. ESHAP brings together etoposide, methylprednisolone, high-dose cytarabine, and cisplatin. The ICE protocol uses ifosfamide, carboplatin, and etoposide. Other options include GVD, which combines gemcitabine, vinorelbine, and liposomal doxorubicin, and IGEV, which uses ifosfamide, gemcitabine, and vinorelbine.^[1]

Additional regimens that doctors may consider include GDP, combining gemcitabine, dexamethasone, and cisplatin, or DICEP, which brings together dexamethasone, cyclophosphamide, etoposide, cisplatin, and mesna. For some patients, particularly those who may not tolerate intensive therapy, gentler options like COPP (cyclophosphamide, vincristine, procarbazine, and prednisone) or CEP (lomustine, etoposide, prednisone, and chlorambucil) might be considered.^[2]

Each of these drug combinations works by attacking cancer cells in different ways. Some drugs damage the DNA inside cancer cells, preventing them from dividing. Others interfere with the cellular machinery that cancer cells need to grow and multiply. By combining several drugs with different mechanisms of action, doctors aim to overcome the resistance that has developed and achieve better disease control.

Targeted Therapy Options

Beyond traditional chemotherapy, several targeted therapy drugs have become important treatment options for refractory Hodgkin lymphoma. These medications work differently from standard chemotherapy by targeting specific molecules on or inside cancer cells, which helps limit damage to normal, healthy cells.^[2]

Brentuximab vedotin (marketed as Adcetris) represents one of the most significant advances in treating relapsed or refractory Hodgkin lymphoma. This medication is an antibody-drug conjugate, which means it combines an antibody that specifically recognizes a protein called CD30 found on Hodgkin lymphoma cells with a powerful chemotherapy drug. The antibody acts like a guided missile, delivering the chemotherapy directly to the cancer cells while sparing most normal cells from exposure.^[1]

Another targeted therapy option is bendamustine (Treanda), which can be used as a single agent for treating refractory disease. This drug works by damaging the DNA in cancer cells, preventing them from growing and dividing. It has shown effectiveness in patients whose disease has not responded to other treatments.^[1]

Immunotherapy: Checkpoint Inhibitors

A revolutionary class of drugs called checkpoint inhibitors has transformed treatment for refractory Hodgkin lymphoma. These medications work by removing the brakes on the body’s immune system, allowing it to recognize and attack cancer cells more effectively. Hodgkin lymphoma cells often exploit certain molecular pathways to hide from immune surveillance; checkpoint inhibitors block these escape mechanisms.^[1]

Two checkpoint inhibitors approved for refractory Hodgkin lymphoma are nivolumab (Opdivo) and pembrolizumab (Keytruda). Both drugs target a molecule called PD-1 found on immune cells. By blocking PD-1, these medications help T cells (a type of white blood cell) maintain their ability to fight cancer cells. These treatments have shown remarkable effectiveness in some patients with refractory disease, leading to responses that can be long-lasting.^[1]

The side effects of checkpoint inhibitors differ from traditional chemotherapy. Because these drugs activate the immune system, they can sometimes cause the immune system to attack normal tissues, leading to inflammation in organs such as the lungs, liver, intestines, or hormone-producing glands. Most side effects are manageable, but they require careful monitoring by healthcare providers.

Stem Cell Transplantation

For many patients with refractory Hodgkin lymphoma, particularly those who are relatively young and otherwise healthy, stem cell transplantation represents a potentially curative approach. The most common type used initially is autologous stem cell transplantation, where the patient’s own stem cells are collected and stored before intensive high-dose chemotherapy is administered.^[1]

The logic behind stem cell transplantation is straightforward but powerful. High-dose chemotherapy can kill more cancer cells than standard doses, but it also destroys the bone marrow, which produces blood cells. By collecting the patient’s stem cells beforehand and returning them after the intensive chemotherapy, doctors can rescue the bone marrow, allowing it to recover and resume normal blood cell production.^[1]

If Hodgkin lymphoma persists or returns after an autologous transplant, some patients may be candidates for an allogeneic stem cell transplant, where stem cells come from another person, usually a closely matched donor. This type of transplant carries additional risks because the donor immune cells can attack the recipient’s tissues, causing a condition called graft-versus-host disease. However, these donor immune cells may also help fight any remaining lymphoma cells.^[2]

Stem cell transplantation is a major procedure that requires hospitalization and carries risks including serious infections, bleeding, organ damage, and potential long-term complications. The decision to proceed with transplant involves careful evaluation of the potential benefits against these risks, considering each patient’s specific situation.

Radiation Therapy

For some patients with refractory Hodgkin lymphoma, particularly when the disease is limited to only one lymph node area and they haven’t previously received radiation to that region, radiation therapy may be offered. This treatment uses high-energy rays or particles to destroy cancer cells in a specific area of the body. It can be given alone or combined with chemotherapy.^[2]

A specific type called involved site radiation therapy (ISRT) focuses the radiation precisely on the areas affected by lymphoma, minimizing exposure to surrounding healthy tissues. Radiation may also be used as part of preparation for a stem cell transplant in some cases.^[1]

Promising Treatments in Clinical Trials

While standard treatments have helped many patients with refractory Hodgkin lymphoma, researchers continue developing innovative therapies that offer hope for those who need additional options. Clinical trials test these new approaches, evaluating their safety and effectiveness before they become widely available. Understanding what Phase I, Phase II, and Phase III trials mean can help patients navigate their options: Phase I trials primarily assess safety and determine appropriate dosing, Phase II trials evaluate whether the treatment works and continues monitoring safety, and Phase III trials compare the new treatment directly with standard therapies.^[10]

CAR T-Cell Therapy

One of the most exciting areas of investigation involves CAR T-cell therapy, a form of personalized immunotherapy. Specifically, anti-CD30-CAR T cells are being studied in clinical trials for refractory Hodgkin lymphoma. This approach involves collecting a patient’s own T cells (immune cells) and genetically modifying them in a laboratory to produce special receptors called chimeric antigen receptors (CARs) on their surface. These engineered receptors are designed to recognize and bind to CD30, a protein abundant on Hodgkin lymphoma cells.^[1]

After modification, these CAR T cells are multiplied to create millions of copies and then infused back into the patient. Once in the body, they seek out and destroy cells displaying the CD30 protein. This therapy essentially turns the patient’s immune system into a targeted weapon against their cancer. Clinical trials are evaluating how well this approach works in patients whose disease has not responded to other treatments, including those who have relapsed after stem cell transplantation.

Additional Checkpoint Inhibitors

Beyond the approved checkpoint inhibitors nivolumab and pembrolizumab, researchers are testing additional medications that work on similar principles. Atezolizumab (Tecentriq) is another checkpoint inhibitor being investigated in clinical trials for Hodgkin lymphoma. It targets a slightly different part of the immune checkpoint system, blocking a molecule called PD-L1 rather than PD-1, though the ultimate goal is the same: unleashing the immune system against cancer cells.^[1]

Researchers are also exploring combinations of checkpoint inhibitors with other therapies to see if they can achieve better results than using these drugs alone. The goal is to find ways to help more patients benefit from immunotherapy and to deepen and prolong responses in those who do respond.

Novel Targeted Agents

Several other targeted therapies are under investigation in clinical trials. Bortezomib (Velcade) and carfilzomib (Kyprolis) are proteasome inhibitors, drugs that interfere with the cellular machinery responsible for breaking down proteins inside cells. By blocking this process, these medications cause cancer cells to accumulate damaged proteins, eventually leading to cell death. While these drugs are already used for other blood cancers, researchers are studying whether they can help patients with refractory Hodgkin lymphoma.^[1]

Everolimus (Afinitor) represents another class of targeted therapy being tested. This drug blocks a cellular pathway called mTOR, which cancer cells often use to fuel their growth and survival. By inhibiting this pathway, everolimus may slow or stop the growth of Hodgkin lymphoma cells. Clinical trials are evaluating its effectiveness and safety in patients whose disease has proven resistant to standard treatments.^[1]

Understanding Clinical Trial Phases and Results

When reading about clinical trials, it helps to understand what preliminary results mean. Early-phase trials might report that a treatment led to “improvement in clinical parameters” or “symptom reduction” in some patients. These are encouraging signs, but they don’t guarantee that the treatment will work for everyone or that it will be better than existing options. That’s why trials progress through multiple phases, gathering more evidence at each step.^[3]

Some clinical trials report positive safety profiles, meaning that the treatment appears to be reasonably well-tolerated without causing unacceptable side effects. This is crucial information, especially for patients who may have already experienced significant treatment-related complications from previous therapies. The goal is always to find treatments that effectively fight the cancer while preserving quality of life as much as possible.

Geographic Availability of Clinical Trials

Clinical trials for refractory Hodgkin lymphoma are being conducted at medical centers around the world. In the United States, major cancer centers often lead these studies, but trials may also be available at community hospitals through research networks. European countries, including those in the European Union, also host numerous trials. Some trials are international, enrolling patients from multiple countries simultaneously. Your healthcare team can help you identify trials for which you might be eligible and determine whether participating would require traveling to a different location.^[10]

Most Common Treatment Methods

• Combination Chemotherapy
  • DHAP regimen combining dexamethasone, cisplatin, and cytarabine
  • ESHAP protocol using etoposide, methylprednisolone, cisplatin, and cytarabine
  • ICE combination with ifosfamide, carboplatin, and etoposide
  • GVD regimen featuring gemcitabine, vinorelbine, and liposomal doxorubicin
  • IGEV protocol combining ifosfamide, gemcitabine, and vinorelbine
• Targeted Therapy
  • Brentuximab vedotin (Adcetris), an antibody-drug conjugate targeting CD30 protein on lymphoma cells
  • Bendamustine (Treanda), a drug that damages cancer cell DNA
• Immunotherapy
  • Nivolumab (Opdivo), a checkpoint inhibitor that blocks PD-1 to enhance immune response
  • Pembrolizumab (Keytruda), another PD-1 blocking antibody that activates immune cells
• Stem Cell Transplantation
  • Autologous stem cell transplant using the patient’s own stem cells after high-dose chemotherapy
  • Allogeneic stem cell transplant using donor stem cells for patients who relapse after autologous transplant
• Radiation Therapy
  • Involved site radiation therapy (ISRT) targeting specific lymph node areas
  • Radiation as part of transplant preparation regimens